News &
Events

Press Releases

Follow CatalYm’s journey and learn more
about our most recent milestones

December 2, 2025

CatalYm Announces First Patient Dosed in Phase 2b Trial Evaluating Visugromab in Combination with Chemoimmunotherapy as Second-Line Treatment in Metastatic Non-squamous NSCLC

- Read More

October 20, 2025

CatalYm Presents Long-Term Phase 1/2a Data Confirming Sustained Responses with Visugromab in CPI-Refractory Tumors at ESMO 2025

- Read More

October 17, 2025

CatalYm Presents Phase 2 Data in Neoadjuvant Bladder Cancer Demonstrating Substantial Increase of Anti-Tumor Activity for Visugromab in Combination with PD-1 Inhibitor at ESMO

- Read More

Load MoreLoading

Meet us at the following
conferences & events

JP Morgan Healthcare Conference 2026

Jan 12 - Jan 15, 2026
San Francisco

Read More

Annual Conference on Sarcopenia, Cachexia, and Wasting Disorders 2025

Dec 11 - Dec 13, 2025
Rome, Italy

Read More

WordPress Cookie Notice by Real Cookie Banner